{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:53:48Z","timestamp":1789077228339,"version":"build-2803163510"},"reference-count":51,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Anemia is a common problem when patients present with cancer, and it can worsen during treatment. Anemia can directly impact the cognitive and physical quality of life and may impair fitness for oncological therapy. The most common cause of anemia is iron deficiency. Newer intravenous (IV) iron formulations offer a safe and rapidly effective treatment option. We performed a systematic mapping review of randomized controlled trials (RCTs) evaluating intravenous iron therapy in patients with cancer and anemia and their outcomes. A total of 23 RCTs were identified. The median number of patients enrolled was 104 (IQR: 60\u2013134). A total of 5 were focused on surgical outcomes (4 preoperative, 1 postoperative), and 15 were in adjuvant therapies for a variety of tumor types (breast, colorectal, lung, gynecological, myeloid, and lymphomas), 10 of which were in combination with erythropoietin-stimulating agents (ESAs) therapy, 2 in radiotherapy, and 1 in palliative care. Overall, the studies reported that the use of IV iron increased hemoglobin concentration and decreased transfusion rates during different cancer treatment regimes. IV iron can be administered safely throughout the cancer treatment pathway from primary surgery to the palliative setting. More studies are needed to demonstrate net clinical outcomes.<\/jats:p>","DOI":"10.3390\/curroncol30090569","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T10:53:47Z","timestamp":1692874427000},"page":"7836-7851","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials"],"prefix":"10.3390","volume":"30","author":[{"given":"Jayne","family":"Lim","sequence":"first","affiliation":[{"name":"School of Medicine, University of Western Australia, Perth, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Auerbach","sequence":"additional","affiliation":[{"name":"Department of Medicine, Georgetown University, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-7673","authenticated-orcid":false,"given":"Beth","family":"MacLean","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Western Australia, Perth, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annas","family":"Al-Sharea","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Western Australia, Perth, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Richards","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Western Australia, Perth, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1017\/S1368980008002401","article-title":"Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993\u20132005","volume":"12","author":"McLean","year":"2009","journal-title":"Public Health Nutr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.2019004017","article-title":"How I treat cancer-associated anemia","volume":"136","author":"Gilreath","year":"2020","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdh235","article-title":"The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials","volume":"15","author":"Cella","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/sj.bjc.6600247","article-title":"The level of haemoglobin in anaemic cancer patients correlates positively with quality of life","volume":"86","author":"Lind","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/jamaoncol.2015.3113","article-title":"JAMA Oncology Patient Page. Performance Status in Patients With Cancer","volume":"1","author":"West","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.ejso.2015.09.009","article-title":"The impact of adjuvant chemotherapy timing on overall survival following colorectal cancer resection","volume":"41","author":"Nachiappan","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"58S","DOI":"10.1016\/j.amjmed.2003.12.013","article-title":"Prevalence and outcomes of anemia in surgery: A systematic review of the literature","volume":"116","author":"Shander","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_8","first-page":"370","article-title":"Pre-operative anaemia: Prevalence, consequences and approaches to management","volume":"13","author":"Munoz","year":"2015","journal-title":"Blood Transfus."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.5694\/mja2.51725","article-title":"The management of peri-operative anaemia in patients undergoing major abdominal surgery in Australia and New Zealand: A prospective cohort study","volume":"217","author":"Collaborative","year":"2022","journal-title":"Med. J. Aust."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-016-3960-3","article-title":"The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: A systematic review and meta-analysis","volume":"160","author":"Raphael","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1001\/jama.2011.749","article-title":"Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: A systematic review and meta-analysis","volume":"305","author":"Biagi","year":"2011","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"434","DOI":"10.6004\/jnccn.2012.0044","article-title":"A perspective on the evolution of management of cancer- and chemotherapy-induced anemia","volume":"10","author":"Rodgers","year":"2012","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","article-title":"Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines","volume":"29","author":"Aapro","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.ejca.2004.07.015","article-title":"EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer","volume":"40","author":"Bokemeyer","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(03)01163-X","article-title":"Breast cancer trial with erythropoietin terminated unexpectedly","volume":"4","author":"Investigators","year":"2003","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bohlius, J., Langensiepen, S., Schwarzer, G., Seidenfeld, J., Piper, M., Bennet, C., and Engert, A. (2004). Erythropoietin for patients with malignant disease. Cochrane Database Syst. Rev., CD003407.","DOI":"10.1002\/14651858.CD003407.pub2"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jtho.2019.10.005","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC","volume":"15","author":"Gascon","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bjc.6605498","article-title":"Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes","volume":"102","author":"Glaspy","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.lungcan.2011.12.015","article-title":"Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses","volume":"76","author":"Vansteenkiste","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","article-title":"The safety of intravenous iron preparations: Systematic review and meta-analysis","volume":"90","author":"Avni","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","article-title":"A typology of reviews: An analysis of 14 review types and associated methodologies","volume":"26","author":"Grant","year":"2009","journal-title":"Health Info. Libr. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bja.2020.04.087","article-title":"Patient blood management interventions do not lead to important clinical benefits or cost-effectiveness for major surgery: A network meta-analysis","volume":"126","author":"Roman","year":"2021","journal-title":"Br. J. Anaesth"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gurusamy, K.S., Nagendran, M., Broadhurst, J.F., Anker, S.D., and Richards, T. (2014). Iron therapy in anaemic adults without chronic kidney disease. Cochrane Database Syst. Rev., Cd010640.","DOI":"10.1002\/14651858.CD010640.pub2"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ansarinejad, N., Abbasi, B., Sadat Rasul, M.S., Fardad, F., and Ramim, T. (2016). The Effectiveness of Ferric Carboxymaltose on the Improvement of Chronic Iron Deficiency Anemia in Patients With Colon Cancer: A Controlled Randomized Clinical Trial. J. Obstet. Gynecol. Cancer Res., 1.","DOI":"10.17795\/jogcr-8006"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1548-5315(12)70022-0","article-title":"IV iron sucrose for cancer and\/or chemotherapy-induced anemia in patients treated with erythropoiesis-stimulating agents","volume":"8","author":"Anthony","year":"2011","journal-title":"Community Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ajh.21779","article-title":"Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia","volume":"85","author":"Auerbach","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2006.10.4620","article-title":"Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia","volume":"26","author":"Bastit","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ygyno.2009.12.004","article-title":"Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy","volume":"116","author":"Dangsuwan","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/02692163221145604","article-title":"The ICaRAS randomised controlled trial: Intravenous iron to treat anaemia in people with advanced cancer-feasibility of recruitment, intervention and delivery","volume":"37","author":"Dickson","year":"2023","journal-title":"Palliat Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/20742835.2017.1321219","article-title":"The severity and optimal management of iron deficiency and anaemia before radiation for cervical cancer at the University of Pretoria Academic Hospitals","volume":"9","author":"Dreyer","year":"2017","journal-title":"South. Afr. J. Gynaecol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/bjs.6688","article-title":"Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery","volume":"96","author":"Edwards","year":"2009","journal-title":"Br. J. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Fung, P.L.P., Lau, V.N.M., Ng, F.F., Leung, W.W., Mak, T.W.C., and Lee, A. (2022). Perioperative changes in haemoglobin and ferritin concentrations from preoperative intravenous iron isomaltoside for iron deficiency anaemia in patients with colorectal cancer: A pilot randomised controlled trial. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0270640"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.34172\/ipp.2021.32","article-title":"Treatment of chemotherapy induced anemia; a randomized clinical trial to compare quality of life in patients taking intravenous versus oral iron","volume":"7","author":"Hajigholami","year":"2020","journal-title":"Immunopathol. Persa"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.leu.2404562","article-title":"Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study","volume":"21","author":"Hedenus","year":"2007","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12032-014-0302-3","article-title":"Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy","volume":"31","author":"Hedenus","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1634\/theoncologist.12-2-231","article-title":"Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy","volume":"12","author":"Henry","year":"2007","journal-title":"Oncologist"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/bjs.10328","article-title":"Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer","volume":"104","author":"Keeler","year":"2017","journal-title":"Br. J. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2006.11.014","article-title":"Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy","volume":"105","author":"Kim","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_43","first-page":"310","article-title":"Single-dose intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of post-operative anaemia in colorectal cancer patients: A randomised controlled trial","volume":"20","author":"Vives","year":"2022","journal-title":"Blood Transfus."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1634\/theoncologist.2010-0020","article-title":"Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: Open-label, randomized controlled study","volume":"15","author":"Maccio","year":"2010","journal-title":"Oncologist"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ajh.26376","article-title":"Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD)","volume":"96","author":"Makharadze","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/ajco.12762","article-title":"Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents","volume":"14","author":"Noronha","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.2007.12.2051","article-title":"Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha","volume":"26","author":"Pedrazzoli","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2010.30.3644","article-title":"Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia","volume":"29","author":"Steensma","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1016\/S2352-3026(22)00402-1","article-title":"Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): A multicentre, open-label, randomised, controlled trial","volume":"10","author":"Talboom","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/anae.14659","article-title":"The impact of pre-operative intravenous iron on quality of life after colorectal cancer surgery: Outcomes from the intravenous iron in colorectal cancer-associated anaemia (IVICA) trial","volume":"74","author":"Keeler","year":"2019","journal-title":"Anaesthesia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1200\/jco.2011.29.15_suppl.9031","article-title":"The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial","volume":"29","author":"Steensma","year":"2011","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/9\/569\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:38:34Z","timestamp":1760128714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/9\/569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["curroncol30090569"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30090569","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}